

## 7 References

1. Adair, F. (2002). "Monoclonal antibodies - magic bullets or a shot in the dark." Therapeutics: 53-59.
2. Amlot, P. L., Rawlings, E., Fernando, O. N., Griffin, P. J., Heinrich, G., Schreier, M. H., Castaigne, J. P., Moore, R., Sweny, P. (1995). "Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation." Transplantation **60**(7): 748-56.
3. Anasetti, C., Hansen, J. A., Waldmann, T. A., Appelbaum, F. R., Davis, J., Deeg, H. J., et al. (1994). "Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor." Blood **84**(4): 1320-7.
4. Anasetti, C., Martin, P. J., Storb, R., Appelbaum, F. R., Beatty, P. G., Calori, E., et al. (1991). "Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3." Bone Marrow Transplant **7**(5): 375-81.
5. Bader, P., Beck, J., Schlegel, P. G., Handgretinger, R., Niethammer, D., Klingebiel, T. (1997). "Additional immunotherapy on the basis of increasing mixed hematopoietic chimerism after allogeneic BMT in children with acute leukemia: is there an option to prevent relapse?" Bone Marrow Transplant **20**(1): 79-81.
6. Bader, P., Hancock, J., Kreyenberg, H., Goulden, N. J., Niethammer, D., Oakhill, A., et al. (2002). "Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL." Leukemia **16**(9): 1668-72.
7. Bader, P., Holle, W., Klingebiel, T., Handgretinger, R., Niethammer, D., Beck, J. (1996). "Quantitative assessment of mixed hematopoietic chimerism by polymerase chain reaction after allogeneic BMT." Anticancer Res **16**(4A): 1759-63.
8. Balduzzi, A., Gooley, T., Anasetti, C., Sanders, J. E., Martin, P. J., Petersdorf, E. W., et al. (1995). "Unrelated donor marrow transplantation in children." Blood **86**(8): 3247-56.
9. Basara, N., Blau, I. W., Willenbacher, W., Kiehl, M. G., Fauser, A. A. (2000). "New strategies in the treatment of graft-versus-host disease." Bone Marrow Transplant **25 Suppl 2**: S12-5.
10. Beatty, P. G., Anasetti, C., Hansen, J. A., Longton, G. M., Sanders, J. E., Martin, P. J., et al. (1993). "Marrow transplantation from unrelated donors for

- treatment of hematologic malignancies: effect of mismatching for one HLA locus." Blood **81**(1): 249-53.
11. Beck, J. F., Klingebiel, T., Kreyenberg, H., Schaudt, A., Wolle, W., Niethammer, D., Bader, P. (2002). "[Relapse of childhood ALL, AML and MDS after allogeneic stem cell transplantation can be prevented by donor lymphocyte infusion in a critical stage of increasing mixed chimerism]." Klin Padiatr **214**(4): 201-5.
  12. Belanger, C., Esperou-Bourdeau, H., Bordigoni, P., Jouet, J. P., Souillet, G., Milpied, N., et al. (1993). "Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT." Bone Marrow Transplant **11**(4): 293-7.
  13. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A., Gralnick, H. R., Sultan, C. (1985a). "Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group." Ann Intern Med **103**(3): 460-2.
  14. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A., Gralnick, H. R., Sultan, C. (1985b). "Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group." Ann Intern Med **103**(4): 620-5.
  15. Blaise, D., Kuentz, M., Fortanier, C., Bourhis, J. H., Milpied, N., Sutton, L., et al. (2000). "Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle." J Clin Oncol **18**(3): 537-46.
  16. Blaise, D., Olive, D., Hirn, M., Viens, P., Lafage, M., Attal, M., et al. (1991). "Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients." Bone Marrow Transplant **8**(2): 105-11.
  17. Blaise, D., Olive, D., Michallet, M., Marit, G., Leblond, V., Maraninchi, D. (1995). "Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis." Lancet **345**(8958): 1144-6.
  18. Bluestone, J. A., Abbas, A. K. (2003). "Natural versus adaptive regulatory T cells." Nat Rev Immunol **3**(3): 253-7.
  19. Brown, P. J., Parenteau, G., Dirbas, F., Garsia, R., Goldman, C., Burowski, M., et al. (1991). "Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival." Proc Natl Acad Sci **88**: 2663.

20. Bumgardner, G. L., Hardie, I., Johnson, R. W., Lin, A., Nashan, B., Pescovitz, M. D., Ramos, E., Vincenti, F. (2001). "Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation." Transplantation **72**(5): 839-45.
21. Burdach, S., Laws, H.-J., Sander, A., Körholz, D., Nürberger, W., Mauz-Körholz, C., Heyll, A., Göbel, U. (1995). "IL2-R-alpha monoclonal antibody for modulation of cytokine gene expression and prevention of GVHD in unrelated BMT." Exp Hematol **23**: 745.
22. Cahn, J. Y., Bordigoni, P., Tiberghien, P., Milpied, N., Brion, A., Widjenes, J., et al. (1995). "Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study." Transplantation **60**(9): 939-42.
23. Carswell, C. I., Plosker, G. L., Wagstaff, A. J. (2001). "Daclizumab: a review of its use in the management of organ transplantation." BioDrugs **15**(11): 745-73.
24. Cassens, U., Baumann, C., Hillmann, H., Reinecke, H., Silling, G., Booke, M., Wawer, A., Sibrowski, W. (2003). "Circulatory arrest during PBPC apheresis in an unrelated donor." Transfusion **43**(6): 736-741.
25. Comans-Bitter, W. M., de Groot, R., van den Beemd, R., Neijens, H. J., Hop, W. C., Groeneveld, K., Hooijkaas, H., van Dongen, J. J. (1997). "Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations." J Pediatr **130**(3): 388-93.
26. Creutzig, U., Ritter, J., Zimmermann, M., Reinhardt, D., Hermann, J., Berthold, F., et al. (2001). "Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93." J Clin Oncol **19**(10): 2705-13.
27. Cutler, C., Giri, S., Jeyapalan, S., Paniagua, D., Viswanathan, A., Antin, J. H. (2001). "Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis." J Clin Oncol **19**(16): 3685-91.
28. den Haan, J. M., Sherman, N. E., Blokland, E., Huczko, E., Koning, F., Drijfhout, J. W., et al. (1995). "Identification of a graft versus host disease-associated human minor histocompatibility antigen." Science **268**(5216): 1476-80.

29. Depper, J. M., Leonard, W. J., Robb, R. J., Waldmann, T. A., Greene, W. C. (1983). "Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation." J Immunol **131**(2): 690-6.
30. Diaz, M. A., Alegre, A., Villa, M., Benito, A., Bernardo, M. R., Lopez-Botet, M., Madero, L. (1997). "Allogeneic peripheral blood progenitor cell (PBPC) transplantation in children with haematological malignancies." Br J Haematol **96**(1): 161-4.
31. Elmaagacli, A. H., Beelen, D. W., Trenn, G., Schmidt, O., Nahler, M., Schaefer, U. W. (1999). "Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation." Bone Marrow Transplant **23**(8): 771-7.
32. Ferrant, A., Latinne, D., Bazin, H., Straetmans, N., Cornet, A., de la Parra, B., Michaux, J. L. (1995). "Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1." Bone Marrow Transplant **16**(4): 577-81.
33. Ferrara, J. L. (2000). "Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors." J Hematother Stem Cell Res **9**(3): 299-306.
34. Gluckman, E., Rocha, V., Chevret, S. (2001). "Results of unrelated umbilical cord blood hematopoietic stem cell transplantation." Rev Clin Exp Hematol **5**(2): 87-99.
35. Gustafsson Jernberg, A., Remberger, M., Ringden, O., Winiarski, J. (2003). "Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival." Bone Marrow Transplant **31**(3): 175-81.
36. Haase, R., Wiegand, P., Hirsch, W., Meyer-Bahlburg, A., Diwan, O., Wawer, A., Burdach, S. (2002). "Unusual presentation of central nervous system relapse with oculomotor nerve palsy in a case of CD56-positive acute myeloid leukemia following allogeneic stem cell transplantation." Pediatr Transplant **6**(3): 260-5.
37. Hakimi, J., Chizzonite, R., Luke, D. R., Familletti, P. C., Bailon, P., Kondas, J. A., et al. (1991). "Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys." J Immunol **147**(4): 1352-9.
38. Herbelin, C., Stephan, J. L., Donadieu, J., Le Deist, F., Racadot, E., Wijdenes, J., Fischer, A. (1994). "Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants." Bone Marrow Transplant **13**(5): 563-9.
39. Hertenstein, B., Stefanic, M., Sandherr, M., Bunjes, D., Mertens, T., Arnold, R. (1994). "Treatment of steroid-resistant acute graft-vs-host disease after

- allogeneic marrow transplantation with anti-interleukin-2 receptor antibody (BT563)." Transplant Proc **26**(6): 3114-6.
40. Herve, P., Wijdenes, J., Bergerat, J. P., Bordigoni, P., Milpied, N., Cahn, J. Y., et al. (1990). "Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10)." Blood **75**(4): 1017-23.
41. Hill, G. R., Ferrara, J. L. (2000). "The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation." Blood **95**(9): 2754-9.
42. Jacobsohn, D. A., Vogelsang, G. B. (2002). "Novel pharmacotherapeutic approaches to prevention and treatment of GVHD." Drugs **62**(6): 879-89.
43. Junghans, R. P., Waldmann, T. A., Landolfi, N. F., Avdalovic, N. M., Schneider, W. P., Queen, C. (1990). "Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders." Cancer Res **50**(5): 1495-502.
44. Kernan, N. A., Bartsch, G., Ash, R. C., Beatty, P. G., Champlin, R., Filipovich, A., et al. (1993). "Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program." N Engl J Med **328**(9): 593-602.
45. Kernan, N. A., Bordignon, C., Heller, G., Cunningham, I., Castro-Malaspina, H., Shank, B., et al. (1989). "Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants." Blood **74**(6): 2227-36.
46. Koch, M., Niemeyer, G., Patel, I., Light, S., Nashan, B. (2002). "Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation." Transplantation **73**(10): 1640-6.
47. Kondo, M., Kojima, S., Horibe, K., Kato, K., Matsuyama, T. (2001). "Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children." Bone Marrow Transplant **27**(7): 727-30.
48. Korbling, M., Anderlini, P. (2001). "Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?" Blood **98**(10): 2900-8.
49. Kovarik, J., Wolf, P., Cisterne, J. M., Mourad, G., Lebranchu, Y., Lang, P., et al. (1997). "Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts." Transplantation **64**(12): 1701-5.

50. Kovarik, J. M., Offner, G., Broyer, M., Niaudet, P., Loirat, C., Mentser, M., et al. (2002). "A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations." Transplantation **74**(7): 966-71.
51. Krenger, W., Hill, G. R., Ferrara, J. L. (1997). "Cytokine cascades in acute graft-versus-host disease." Transplantation **64**(4): 553-8.
52. Lenardo, M. J. (1991). "Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis." Nature **353**(6347): 858-61.
53. Leonard, P. A., Woodside, K. J., Gugliuzza, K. K., Sur, S., Daller, J. A. (2002). "Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody." Transplantation **74**(12): 1697-700.
54. Levine, J. E., Wiley, J., Kletzel, M., Yanik, G., Hutchinson, R. J., Koehler, M., Neudorf, S. (2000). "Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD." Bone Marrow Transplant **25**(1): 13-8.
55. Li, C. K., Yuen, P. M., Chik, K. W., Shing, M. M., Li, K., Tsang, K. S., Wong, A., Leung, T. F., Lai, H. (1998). "Allogeneic peripheral blood stem cell transplant in children." Med Pediatr Oncol **30**(3): 147-51.
56. Lickliter, J. D., McGlave, P. B., DeFor, T. E., Miller, J. S., Ramsay, N. K., Verfaillie, C. M., et al. (2000). "Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation." Bone Marrow Transplant **26**(7): 723-8.
57. Locatelli, F., Bruno, B., Zecca, M., Van-Lint, M. T., McCann, S., Arcese, W., et al. (2000). "Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial." Blood **96**(5): 1690-7.
58. Locatelli, F., Uderzo, C., Dini, G., Zecca, M., Arcese, W., Messina, C., et al. (1993). "Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A." Bone Marrow Transplant **12**(6): 627-33.
59. Locatelli, F., Zecca, M., Rondelli, R., Bonetti, F., Dini, G., Prete, A., et al. (2000). "Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial." Blood **95**(5): 1572-9.

60. Malek, T. R., Yu, A., Vincek, V., Scibelli, P., Kong, L. (2002). "CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2." Immunity **17**(2): 167-78.
61. Mielcarek, M., Martin, P. J., Leisenring, W., Flowers, M. E., Maloney, D. G., Sandmaier, B. M., Maris, M. B., Storb, R. (2003). "Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation." Blood.
62. Montagna, D., Maccario, R., Comoli, P., Prete, L., Zecca, M., Giraldi, E., et al. (1996). "Frequency of donor cytotoxic T cell precursors does not correlate with occurrence of acute graft-versus-host disease in children transplanted using unrelated donors." J Clin Immunol **16**(2): 107-14.
63. Nash, R. A., Pepe, M. S., Storb, R., Longton, G., Pettinger, M., Anasetti, C., et al. (1992). "Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate." Blood **80**(7): 1838-45.
64. Nash, R. A., Storb, R. (1996). "Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL." Curr Opin Immunol **8**(5): 674-80.
65. Nashan, B., Moore, R., Amlot, P., Schmidt, A. G., Abeywickrama, K., Soullillou, J. P. (1997). "Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group." Lancet **350**(9086): 1193-8.
66. Niemeyer, G., Koch, M., Light, S., Kuse, E. R., Nashan, B. (2002). "Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients." Am J Transplant **2**(5): 454-60.
67. Offner, G., Broyer, M., Niaudet, P., Loirat, C., Mentser, M., Lemire, J., et al. (2002). "A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients." Transplantation **74**(7): 961-6.
68. Onrust, S. V., Wiseman, L. R. (1999). "Basiliximab." Drugs **57**(2): 207-13; discussion 214.
69. Peters, C., Minkov, M., Gadner, H., Klingebiel, T., Vossen, J., Locatelli, F., et al. (2000). "Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children." Bone Marrow Transplant **26**(4): 405-11.
70. Przepiorka, D., Anderlini, P., Saliba, R., Cleary, K., Mehra, R., Khouri, I., et al. (2001). "Chronic graft-versus-host disease after allogeneic blood stem cell transplantation." Blood **98**(6): 1695-700.

71. Przepiorka, D., Kernan, N. A., Ippoliti, C., Papadopoulos, E. B., Giralt, S., Khouri, I., et al. (2000). "Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease." Blood **95**(1): 83-9.
72. Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H. G., Beatty, P., Hows, J., Thomas, E. D. (1995). "1994 Consensus Conference on Acute GVHD Grading." Bone Marrow Transplant **15**(6): 825-8.
73. Remberger M, Ringden O, Blau IW, Ottinger H, Kremens B, Kiehl MG, et al. (2001). "No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors." Blood **98**(6): 1739-45.
74. Ringden, O., Remberger, M., Persson, U., Ljungman, P., Aldener, A., Andstrom, E., et al. (1995). "Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings." Bone Marrow Transplant **15**(4): 619-25.
75. Roifman, C. M. (2000). "Human IL-2 receptor alpha chain deficiency." Pediatr Res **48**(1): 6-11.
76. Sander, A. (1999). "[GVHD incidence and modulation of cytokines after unrelated BMT in children and adults after treatment with BT563]." Düsseldorf, Med. Fak., Diss.: 1-62.
77. Sarwal, M. M., Yorgin, P. D., Alexander, S., Millan, M. T., Belson, A., Belanger, N., et al. (2001). "Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation." Transplantation **72**(1): 13-21.
78. Schimpl, A., Berberich, I., Kneitz, B., Kramer, S., Santner-Nanan, B., Wagner, S., Wolf, M., Hunig, T. (2002). "IL-2 and autoimmune disease." Cytokine Growth Factor Rev **13**(4-5): 369-78.
79. Schrappe, M., Reiter, A., Ludwig, W. D., Harbott, J., Zimmermann, M., Hiddemann, W., et al. (2000). "Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group." Blood **95**(11): 3310-22.
80. Simpson, D. (2000). "Drug therapy for acute graft-versus-host disease prophylaxis." J Hematother Stem Cell Res **9**(3): 317-25.
81. Small, T. N., Papadopoulos, E. B., Boulad, F., Black, P., Castro-Malaspina, H., Childs, B. H., et al. (1999). "Comparison of immune reconstitution after



- unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions." Blood **93**(2): 467-80.
82. Sterkers, G., Baudouin, V., Ansart-Pirenne, H., Maisin, A., Niaudet, P., Cochat, P., Loirat, C. (2000). "Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipients." Transplant Proc **32**(8): 2757-9.
83. Storb, R. (1995). "Prevention of graft-versus-host disease after bone marrow transplantation." Transplant Proc **27**(5): 2653-6.
84. Storb, R., Deeg, H. J., Whitehead, J., Appelbaum, F., Beatty, P., Bensinger, W., et al. (1986). "Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia." N Engl J Med **314**(12): 729-35.
85. Storek, J., Gooley, T., Siadak, M., Bensinger, W. I., Maloney, D. G., Chauncey, T. R., et al. (1997). "Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease." Blood **90**(12): 4705-9.
86. Sullivan, K. M., Agura, E., Anasetti, C., Appelbaum, F., Badger, C., Bearman, S., et al. (1991). "Chronic graft-versus-host disease and other late complications of bone marrow transplantation." Semin Hematol **28**(3): 250-9.
87. Sullivan, K. M., Storb, R., Buckner, C. D., Fefer, A., Fisher, L., Weiden, P. L., et al. (1989). "Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms." N Engl J Med **320**(13): 828-34.
88. Sullivan, K. M., Weiden, P. L., Storb, R., Witherspoon, R. P., Fefer, A., Fisher, L., et al. (1989). "Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia." Blood **73**(6): 1720-8.
89. Takeshita, T., Asao, H., Ohtani, K., Ishii, N., Kumaki, S., Tanaka, N., Munakata, H., Nakamura, M., Sugamura, K. (1992). "Cloning of the gamma chain of the human IL-2 receptor." Science **257**(5068): 379-82.
90. ter Meulen, C. G., Baan, C. C., Hene, R. J., Hilbrands, L. B., Hoitsma, A. J. (2001). "Two doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockade." Transplantation **72**(10): 1709-10.
91. Uchiyama, T., Broder, S., Waldmann, T. A. (1981). "A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells." J Immunol **126**(4): 1393-7.

92. Van Parijs, L., Abbas, A. K. (1998). "Homeostasis and self-tolerance in the immune system: turning lymphocytes off." Science **280**(5361): 243-8.
93. Vincenti, F., Kirkman, R., Light, S., Bumgardner, G., Pescovitz, M., Halloran, P., et al. (1998). "Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group." N Engl J Med **338**(3): 161-5.
94. Vincenti, F., Pace, D., Birnbaum, J., Lantz, M. (2003). "Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation." Am J Transplant **3**(1): 50-2.
95. Waldmann, T. A. (1986). "The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes." Science **232**(4751): 727-32.
96. Weiden, P. L., Sullivan, K. M., Flournoy, N., Storb, R., Thomas, E. D. (1981). "Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation." N Engl J Med **304**(25): 1529-33.
97. Weisdorf, D., Hakke, R., Blazar, B., Miller, W., McGlave, P., Ramsay, N., Kersey, J., Filipovich, A. (1991). "Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation." Transplantation **51**(6): 1197-203.
98. Weiss, L., Reich, S., Slavin, S. (1995). "The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia." Bone Marrow Transplant **16**(3): 457-61.
99. Wells, A. D., Li, X. C., Li, Y., Walsh, M. C., Zheng, X. X., Wu, Z., et al. (1999). "Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance." Nat Med **5**(11): 1303-7.
100. Willenbacher, W., Basara, N., Blau, I. W., Fauser, A. A., Kiehl, M. G. (2001). "Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab." Br J Haematol **112**(3): 820-3.
101. Willerford, D. M., Chen, J., Ferry, J. A., Davidson, L., Ma, A., Alt, F. W. (1995). "Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment." Immunity **3**(4): 521-30.
102. Zecca, M., Locatelli, F. (2000). "Management of graft-versus-host disease in paediatric bone marrow transplant recipients." Paediatr Drugs **2**(1): 29-55.
103. Zecca, M., Prete, A., Rondelli, R., Lanino, E., Balduzzi, A., Messina, C., et al. (2002). "Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome." Blood **100**(4): 1192-200.

104. Zikos, P., Van Lint, M. T., Lamparelli, T., Gualandi, F., Occhini, D., Bregante, S., et al. (1998). "Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse." Haematologica **83**(10): 896-903.